Clinical Trials | February 24, 2026
Novo Nordisk’s "Triple G" drug UBT251 triggers nearly 20% weight loss in 24 weeks
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The paper highlights how conditions common across India—including anemia, inherited hemoglobin disorders, and glucose-6-phosphate dehydrogenase (G6PD) deficiency—can significantly distort HbA1c readings
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge
Globally, Abbott has received reports of 736 severe adverse events linked to the issue, including seven deaths (none in the US)
According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic
Uncontrolled diabetes in pregnancy dramatically increases the risk of pre-eclampsia, stillbirth, birth injuries, and long-term cardiometabolic diseases
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
